[go: up one dir, main page]

UY26514A1 - "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES". - Google Patents

"COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES".

Info

Publication number
UY26514A1
UY26514A1 UY26514A UY26514A UY26514A1 UY 26514 A1 UY26514 A1 UY 26514A1 UY 26514 A UY26514 A UY 26514A UY 26514 A UY26514 A UY 26514A UY 26514 A1 UY26514 A1 UY 26514A1
Authority
UY
Uruguay
Prior art keywords
composition
damaged tissues
treatment
agent
wound
Prior art date
Application number
UY26514A
Other languages
Spanish (es)
Inventor
Michael John Davies
Jonathan Paul Huggins
Fraser Stuart Mcinstosh
Nicholas Laurence Occleston
Fraser Stuart Mcintosh
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY26514A1 publication Critical patent/UY26514A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un agente farmacéutico para uso en el tratamiento (por ejemplo, curación) de tejidos danados, tal como una herida, comprendiendo el agente farmacéutico una composición que comprende: (a) un factor de crecimiento; (b) un agente inhibidor; y, opcionalmente, (c) un vehículo, diluyente o excipiente farmaceúticamente aceptable; pudiendo el agente inhibir la acción de al menos una proteína adversa específica (por ejemplo, una proteasa específica) que está regulada positivamente en un entorno de tejido danado, tal como una herida.A pharmaceutical agent for use in treating (eg, healing) damaged tissues, such as a wound, is disclosed, the pharmaceutical agent comprising a composition comprising: (a) a growth factor; (b) an inhibiting agent; and optionally (c) a pharmaceutically acceptable carrier, diluent, or excipient; the agent being able to inhibit the action of at least one specific adverse protein (eg, a specific protease) that is up-regulated in a damaged tissue environment, such as a wound.

UY26514A 1999-12-29 2000-12-28 "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES". UY26514A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
UY26514A1 true UY26514A1 (en) 2001-07-31

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26514A UY26514A1 (en) 1999-12-29 2000-12-28 "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES".

Country Status (12)

Country Link
EP (1) EP1242120A2 (en)
JP (1) JP2003519193A (en)
AR (1) AR027122A1 (en)
AU (1) AU1878201A (en)
CA (1) CA2395487A1 (en)
CO (1) CO5271671A1 (en)
EC (1) ECSP003859A (en)
GB (1) GB9930768D0 (en)
GT (1) GT200000224A (en)
PE (1) PE20011095A1 (en)
UY (1) UY26514A1 (en)
WO (1) WO2001049309A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE544855T1 (en) 2000-10-16 2012-02-15 Genentech Inc WISP POLYPEPTIDES, AND THEIR THERAPEUTIC USES
WO2003013569A2 (en) 2001-07-27 2003-02-20 The Board Of Regents, The University Of Texas System Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
WO2003029819A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Method of screening preventive/remedy for bone/joint diseases
WO2004014937A2 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
AU2004312090B2 (en) 2003-12-31 2008-08-14 The Board Of Regents, The University Of Texas System Pharmaceutical composition for thrombin peptide derivatives
CN101365715B (en) * 2005-10-07 2013-03-27 P·安杰莱蒂分子生物学研究所 Matrix metalloproteinase 11 vaccine
WO2008060622A2 (en) * 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
KR101629504B1 (en) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 Composition for improving skin conditions containing a combination of cytokines
JP2020517615A (en) * 2017-04-21 2020-06-18 プレシゲン，インコーポレイテッド Delivery of autologous cells containing matrix metalloproteinases for the treatment of scleroderma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (en) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd Novel composition for external use
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
CA2395487A1 (en) 2001-07-12
WO2001049309A3 (en) 2002-02-28
AR027122A1 (en) 2003-03-12
ECSP003859A (en) 2002-09-27
EP1242120A2 (en) 2002-09-25
WO2001049309A2 (en) 2001-07-12
JP2003519193A (en) 2003-06-17
PE20011095A1 (en) 2001-10-27
AU1878201A (en) 2001-07-16
GB9930768D0 (en) 2000-02-16
GT200000224A (en) 2002-06-15
CO5271671A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
BR0014384A (en) Compounds for the treatment of ischemia
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
AR020055A1 (en) A PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A SUBSTANCE OF ACTIVE ENAMEL, USES OF SUCH COMPOSITION AND A METHOD TO PREPARE THE SAME.
ATE218581T1 (en) CYCLOSPORINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION
BR0207760A (en) Pharmaceutical composition, use thereof, methods for treating pain and inflammation, and process for preparing a composition
AR010385A1 (en) PROPIOPHENONE-DERIVED COMPOUND, PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE OF SUCH COMPOUND.
MY130477A (en) Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome
NO20004282D0 (en) Matrix protein preparations for wound healing
ATE450265T1 (en) PHARMACEUTICAL MIXTURE FOR THE TREATMENT OF CANCER CONTAINING DIOXOLANE NUCLEOSIDE ANALOGUES
EA200500804A1 (en) Topical Anti-infective Compositions
DE69116380D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME
BRPI0406796A (en) Methods for treating benign prostatic hypertrophy, reducing a symptom associated with it, reducing prostate size in a human subject, and for bhp prophylaxis, oral unit dose pharmaceutical composition, and use of lonidamine or a lonidamine analogue
UY26514A1 (en) "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES".
ATE322878T1 (en) GALENIC FORMULATION CONTAINING BIOTIN
ES2124983T3 (en) USE OF A SUBSTANCE P ANTAGONIST FOR THE TREATMENT OF RED SKIN STAINS OF NEUROGENOUS ORIGIN.
BR0010983A (en) Preparations for the application of anti-inflammatory agents
DE69909747D1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS
CO5241355A1 (en) PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS
GEP20043231B (en) Resorcinol Composition
FI932654A0 (en) Hydroxamsyraderivat, som hindrar lipoxigenas
AR005730A1 (en) FORM OF FANCICLOVIR, PROCEDURE FOR PREPARING IT, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS AND THE USE OF SUCH FORM -FANCICLOVIR MONOIDRATE.
ATE270110T1 (en) MEDICINAL PRODUCT CONTAINING TISSUE INHIBITOR OF METALLOPROTEINASES-2 (TIMP-2) AS AN OSTEOANABOLIC SUBSTANCE
BR0308734A (en) Compound, pharmaceutical composition, use of compound, and method for preventing or treating infection
BR0303384A (en) Citalopram And Its Uses In The Treatment Of High Blood Pressure

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120529